Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

149 results about "Sphingomyelin" patented technology

Sphingomyelin (SPH, ˌsfɪŋɡoˈmaɪəlɪn) is a type of sphingolipid found in animal cell membranes, especially in the membranous myelin sheath that surrounds some nerve cell axons. It usually consists of phosphocholine and ceramide, or a phosphoethanolamine head group; therefore, sphingomyelins can also be classified as sphingophospholipids. In humans, SPH represents ~85% of all sphingolipids, and typically make up 10–20 mol % of plasma membrane lipids.

Lactiplantibacillus plantarum 24 and its applications

The present invention provides a Lactiplantibacillus plantarum ( Lactiplantibacillus plantarum ), strain 24, which is deposited in the China General Microbiological Culture Collection Center, deposit number: CGMCC No. 31278. The Lactiplantibacillus plantarum 24 of the present invention can secrete sphingomyelinase to promote the production of ceramide in HaCaT cells; Lactiplantibacillus plantarum 24 or its metabolite or its lysate can up-regulate the expression of key enzymes in the sphingomyelinase and / or ceramide synthesis pathway of skin cells, repair the skin barrier; down-regulate the expression of pro-inflammatory cytokines, inhibit autophagy, and has a good anti-inflammatory effect; at the same time, it also has good antioxidant and whitening effects. The Lactiplantibacillus plantarum 24 or its metabolite or its cell lysate of the present invention can be used in the preparation of products having the above-mentioned effects or functions.
Owner:TIANJIN UNIV OF SCI & TECH +1

Phytobacterium plantarum 24 and application thereof

The invention provides a lactobacillus plantarum 24 which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms, and the preservation number of the lactobacillus plantarum 24 is CGMCC No.31278. The lactobacillus plantarum 24 has the advantages that the lactobacillus plantarum 24 is prepared from lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum, lactobacillus plantarum and lactobacillus plantarum; the plant lactobacillus 24 disclosed by the invention can secrete sphingomyelinase and promote HaCaT cells to generate ceramide; the plant lactobacillus 24 or the metabolite or lysate thereof can up-regulate expression of key enzymes in a synthetic route of skin cell sphingomyelinase and / or ceramide, and repair a skin barrier; expression of proinflammatory cytokines is lowered, autophagy is inhibited, and a good anti-inflammatory effect is achieved; meanwhile, the anti-oxidation and whitening effects are relatively good. The plant lactobacillus 24 or the metabolite or the cell lysate of the plant lactobacillus 24 can be applied to preparation of products with the effects or the effects of the plant lactobacillus 24 and the metabolite or the cell lysate of the plant lactobacillus 24.
Owner:TIANJIN UNIV OF SCI & TECH +1

Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof

A nutritional composition, typically an infant enterically administered nutritional composition, that comprises a milk fat globule membrane component, at least one human milk oligosaccharide and one additional component or a plurality of additional components where the additional component or components include DHA, ARA, Vitamin E, Vitamin C, and sphingomyelin.
Owner:PBM NUTRITIONALS LLC

mRNA delivery using lipid nanoparticles

The present disclosure provides a lipid nanoparticle comprising encapsulated mRNA and at least 30 mol % of a sphingolipid (e.g. sphingomyelin (SM)), and at least one of a sterol and a hydrophilic polymer-lipid conjugate, the lipid nanoparticle comprising a core comprising an electron dense region and an aqueous portion surrounded at least partially by a lipid layer comprising a bilayer and the lipid nanoparticle exhibiting at least a 2-fold increase in gene expression in the liver, spleen and / or bone marrow at 4 or 24 hours post-injection as compared to a lipid nanoparticle encapsulating mRNA with an Onpattro™-type formulation of cationic, ionizable lipid / DSPC or ESM / cholesterol / PEG-lipid at 50 / 10 / 38.5 / 1.5, mol:mol, wherein the gene expression is measured in an animal model by detection of green fluorescent protein (GFP). Further provided are methods of medical treatment and uses of such lipid nanoparticles to treat or prevent a disease condition in a hepatic or non-hepatic tissue or organ.
Owner:THE UNIV OF BRITISH COLUMBIA

Method for simultaneously preparing high-purity sphingomyelin and glycerol phosphocholine

PCT designated stage expiredWO2024259771A1Phosphorus organic compoundsBiochemical engineeringGlycerol
Disclosed in the present invention is a method for simultaneously preparing high-purity sphingomyelin and glycerol phosphocholine. The method comprises the following steps: 1) adding a degradation agent to a phospholipid mixture to degrade phospholipid, so as to obtain a sphingomyelin and glycerol phosphocholine mixture, and carrying out separation by means of a refining method to obtain a crude product; 2) carrying out column chromatography to obtain sphingomyelin having a purity higher than 98%; and 3) obtaining glycerol phosphocholine having a purity higher than 95% by means of a refining method; and 4) drying same to obtain a phospholipid satisfying the pharmaceutical standard. The solvent used in the present invention can be recycled and reused and is environmentally friendly, and the method has mild reaction conditions, good selectivity, low requirement for the raw material purity, and a relatively low production cost, and is beneficial to industrial mass production.
Owner:GUANGZHOU HANFANG PHARMA CO LTD

Biomarker combination and application thereof in IDH-1 gene mutation detection

The invention belongs to the technical field of biological detection, and particularly relates to a biomarker combination and application thereof in IDH-1 gene mutation detection. The biomarker combination comprises one or more of the following lipid metabolites: a third component of high-density lipoprotein-triglyceride, a fourth component of high-density lipoprotein-triglyceride, high-density lipoprotein-triglyceride, lactic acid and sphingomyelin. Whether a glioblastoma patient carries IDH-1 gene mutation or not is judged through a plurality of biomarkers, the method has the advantages of being good in sensitivity and specificity, small in patient trauma, capable of overcoming individual differences and suitable for large-scale screening, and a new solution is provided for clinical patient diagnosis.
Owner:ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY +1

Lipid composition for preparing extracellular vesicles

The invention discloses a lipid composition for preparing extracellular vesicles, which is prepared from the following lipid substances in percentage by mass: 2 to 18 percent of phosphatidylcholine, 2 to 14 percent of phosphatidylethanolamine, 7 to 27 percent of sphingomyelin, 0.5 to 7 percent of ceramide, 1.5 to 2.5 percent of phosphatidylinositol, 30 to 70 percent of cholesterol and 5 to 8 percent of phosphatidylserine, the fatty acid carbon number of the lipid substance satisfies the following conditions: the fatty acid carbon number of phosphatidylcholine is 16-20, the fatty acid carbon number of phosphatidyl ethanolamine is 16-18, the fatty acid carbon number of sphingomyelin is 16-24, the fatty acid carbon number of ceramide is 16-24, the fatty acid carbon number of phosphatidylinositol is 16-20, the fatty acid carbon number of phosphatidylserine is 18-24, and the molar ratio of cholesterol to sphingomyelin is 4-7. The extracellular vesicles are prepared from the lipid composition and used for biomarkers or drug carriers, and efficient oral drug delivery is achieved.
Owner:JIANGNAN UNIV

Liposomes for inhibiting biofilm formation

The present invention relates to a composition comprising, preferably consisting of, (i) a single empty liposome, wherein said single empty liposome is selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; or (b) an empty liposome consisting of sphingomyelin; or (ii) a mixture of empty liposomes; wherein said mixture of empty liposomes comprises, preferably consists of, at least one empty liposome selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; (b) an empty liposome consisting of sphingomyelin; and (c) an empty liposome comprising, preferably consisting of, phosphatidylcholine and sphingomyelin; and at least one empty liposome independently of each other selected from an empty liposome comprising, preferably consisting of, lipids or phospholipids selected from cholesterol, sphingomyelins, ceramides, phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines, diacylglycerols, and phosphatidic acids containing one or two or more saturated or unsaturated fatty acids longer than 4 carbon atoms and up to 28 carbon atoms; for use in a method for preventing or reducing biofilm formation or for eradicating or reducing existing biofilm.
Owner:COMBIOXIN SA

Specific metabolism marker combination for diagnosing ovarian cancer and application thereof

The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer and application thereof, and belongs to the field of markers for detecting ovarian cancer. The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer. The specific metabolic marker combination comprises phosphatidylcholine 36: 6, sphingomyelin d40: 2 and sphingomyelin d41: 2. According to the invention, a metabonomics technology is used to screen out a specific metabolism marker combination for diagnosing ovarian cancer, and the specific metabolism marker combination has high sensitivity in ovarian cancer diagnosis and has high diagnosis capability for ovarian cancer diagnosis. The specific metabolic marker combination also has high specificity in ovarian cancer diagnosis, but is not applicable to diagnosis of endometrial cancer and cervical cancer. In addition, the plasma sample acquisition mode has the advantages of non-invasiveness and convenience, and has a wide application prospect in the research of biomarkers.
Owner:HARBIN METANOTITIA INC

Anti-wrinkle repairing face cream and preparation method thereof

PendingCN119185100Amaintain therapeutic effectCosmetic preparationsMixing methodsMessenger moleculeApoptosis
The invention discloses an anti-wrinkle repairing face cream and a preparation method thereof, a mixture of cetyl-PG hydroxyethyl palmitamide is ceramide E. The ceramide E in the anti-wrinkle repairing face cream has an important regulating effect on life activities such as cell differentiation, proliferation, apoptosis and aging, and the ceramide is used as a main component of intercellular lipid of skin cuticle, so that the anti-wrinkle repairing face cream has a good anti-wrinkle effect on the skin cuticle. The protein not only serves as a second messenger molecule in a sphingomyelin pathway, but also plays an important role in an epidermal stratum corneum formation process, and has the effects of maintaining a skin barrier, preserving moisture, resisting aging, whitening, treating diseases and the like.
Owner:HUANGSHAN HEXIU BIOTECHNOLOGY CO LTD

Early-stage accurate screening method for ovarian cancer based on triple lipid metabolite chemical crosslinking

The invention relates to the technical field of biotechnology and medical detection, in particular to an ovarian cancer early-stage accurate screening method based on triple lipid metabolite chemical crosslinking, which comprises the following steps: sample collection: collecting a serum sample of a person to be detected; lipid metabolite extraction: extracting lipid metabolite from the serum sample; detection of triple lipid metabolites: simultaneously detecting the contents of sphingomyelin (SM), phosphatidylcholine (PC) and cholesteryl ester (CE) in the lipid metabolites by adopting a liquid chromatography-mass spectrometry technology, and by simultaneously detecting the three lipid metabolites of sphingomyelin (SM), phosphatidylcholine (PC) and cholesteryl ester (CE) and carrying out chemical cross-linking analysis, the content of the triple lipid metabolites in the lipid metabolites can be detected; and calculating the triple lipid metabolite index (TLMI), so that the abnormal lipid metabolism condition of the ovarian cancer patient can be more comprehensively and accurately reflected, and the sensitivity and the specificity of early screening of the ovarian cancer are improved.
Owner:刘文媛

Covalently modified antigens for improved immune response and / or stability

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.
Owner:DEFENSE THERAPY INC

Liposome composition and liposome-containing pharmaceutical composition

A liposome composition comprising (A) liposomes comprising a dihydrosphingomyelin and a diacylglycerol-polyethylene glycol, (B) a drug, and (C) a sulfuric acid salt and / or sucrose octasulfate, and in which (A) encapsulates (B), wherein the diacylglycerol-polyethylene glycol is distearoylglycerol-polyethylene glycol, and (B) is 4-(3-chloro-4-(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide represented by formula (I) or its pharmaceutically acceptable salt.
Owner:EISAI R&D MANAGEMENT CO LTD

Multifunctional sphingomyelin and ceramide

PCT designated stageWO2026017703A3Phosphorus organic compoundsStainingClick chemistry
The invention introduces novel chemical modifications to sphingomyelin and ceramide molecules, making them readily available for targeted staining and detection techniques, such as click chemistry.
Owner:JULIUS MAXIMILIANS UNIV WURZBURG

Liposomal compositions for treatment of inflammation

The invention relates to a pharmaceutical composition consisting of a liposomal formulation of a phospholipid component and an aqueous phase, wherein the phospholipid component is selected from the group consisting of phosphatidylcholine, and sphingomyelin, and wherein the phospholipid component comprises a saturated or mono-unsaturated (Z / cis) fatty acid having 14 to 20 carbon atoms. The invention further relates to the use of the pharmaceutical composition in treatment of a condition associated with presence of lipopolysaccharide (LPS), particularly endotoxemia.
Owner:UNIVERSITY OF BERN

Nutritional composition capable of influencing protein expression of brain hippocampus and application of nutritional composition

The invention provides a nutritional composition capable of influencing protein expression of brain hippocampus and application of the nutritional composition. The nutritional composition of the present invention comprises sialic acid, sphingomyelin and phosphatidylcholine, in which the ratio of the sum of the contents of sphingomyelin and phosphatidylcholine to the content of sialic acid is 1: 1 by weight, and the ratio of sphingomyelin to phosphatidylcholine is 0.2: 1 to 1.4: 1 based on the total weight of sphingomyelin and phosphatidylcholine. The composition can increase the gray matter volume of the brain and can improve the expression of BDNFmRNA of the hippocampus and the prefrontal cortex.
Owner:INNER MONGOLIA YILI IND GROUP CO LTD +1

Blood marker for distinguishing lung cancer and non-lung cancer diseases and application thereof

The invention provides a blood marker for distinguishing lung cancer and non-lung cancer diseases and application of the blood marker, and belongs to the technical field of biomarkers. The blood marker for distinguishing lung cancer and non-lung cancer diseases comprises at least five metabolites as follows: phosphatidylethanolamine (36: 4), lysophosphatidylcholine 18: 1e, phosphatidylethanolamine 38: 7e, sphingomyelin d38: 5, dodecanedioic acid, N-acetylputrescine, L-glutamyl-L-glutamine, hippuric acid, trans-cyclohexane-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3-triazole-1, 3, 4- The compound is prepared from 1, 2-dicarboxylic acid, glycochenodeoxycholic acid, allantoic acid, L-valine, methyleucine and 4-guanidinobutyric acid. A diagnosis model is constructed based on the blood marker, and the area under curve (AUC) is greater than 0.77, which indicates that the diagnosis result is accurate and reliable. The invention provides an effective marker for diagnosis of lung cancer and differential diagnosis of lung cancer and non-lung cancer diseases, greatly simplifies experimental operation, and has important clinical diagnosis significance.
Owner:HARBIN METANOTITIA INC

Composition containing anti-wrinkle lipidosome for cosmetic preparation and preparation method

The invention relates to a composition containing anti-wrinkle lipidosome for cosmetic preparation and a preparation method of the composition, and belongs to the technical field of cosmetics. The invention discloses a composition containing anti-wrinkle lipidosome and a preparation method thereof. The composition comprises four plant extracts of purple coneflower, calendula officinalis, salvia officinalis and elderberry, and lipidosome consisting of lecithin, cholesterol, sphingomyelin and ascorbyl palmitate, and is supplemented with components such as a humectant and an emulsifier. According to the composition, through the synergistic effect of the plant extract and the lipidosome, the anti-wrinkle effect is enhanced, and the storage and illumination stability is improved; an extract structure is optimized by a compound fermentation process, and a liposome system is adapted; the components are safe and suitable for multiple skin types, the preparation process is compatible with industrial production, and the pain points that traditional anti-wrinkle products are poor in stability and insufficient in effect are solved.
Owner:GUANGZHOU XUNSHI YUEMEI COSMETICS MANUFACTURING CO LTD

Nutritional composition comprising milk phospholipids and egg phospholipids

The present invention provides a nutritional composition comprising milk phospholipids and egg phospholipids, particularly suitable as a nutritional composition for infants, also as a nutritional support product for pregnant women and as a nutritional supplement for the elderly, in which phosphatidylcholine and sphingomyelin and hence choline are also highly correlated. The invention provides a nutritional composition containing choline with high bioavailability.
Owner:AAK AB(PUBL)

Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation

An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition, in which liposomes encapsulate a drug, with a platinum preparation. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) a platinum preparation, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin; and cholesterols, the liposome composition includes a drug and has an inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the platinum preparation are administered simultaneously or sequentially.
Owner:FUJIFILM CORP

A method for golgi staining of primary neuronal cells based on lipids and application thereof

The application provides a kind of primary neuron cell golgi staining method and application based on lipid, comprising the following steps: 1) extracting, culturing and fixing primary neuron cell;2) selecting one kind of lipid in phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, cholesterol, lecithin;3) the selected lipid is evenly covered on the cell surface, and Golgi staining solution is added for staining;4) remove Golgi staining solution, and use reducing agent for developing reaction;5) optical microscope imaging observation and / or simultaneous radiation X-ray imaging observation;6) the imaging data is analyzed and processed using data processing software.The application successfully stains primary neuron cell, and under the simultaneous radiation X-ray imaging technology, neuron dendrite and morphology can be observed, which lays a good research foundation for using simultaneous radiation X-ray to quantitatively study neuron complete three-dimensional structure and complete three-dimensional fine structure of neuron.
Owner:SHANGHAI ADVANCED RES INST CHINESE ACADEMY OF SCI

Combined pharmaceutical formulation comprising drug-containing liposome composition and immune checkpoint inhibitor

An object of the present invention is to provide a pharmaceutical formulation obtained by combining a liposome composition in which liposomes encapsulate a drug with an immune checkpoint inhibitor. According to the present invention, there is provided a pharmaceutical formulation including (A) a liposome composition in combination with (B) an immune checkpoint inhibitor, in which the liposome composition includes, as constitutional components of a liposome membrane, a hydrophilic polymer-modified diacylphosphatidylethanolamine; a dihydrosphingomyelin, and cholesterols, the liposome composition includes a drug and has art inner water phase containing ammonium sulfate, a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more, and the liposome composition and the immune checkpoint inhibitor are administered simultaneously or sequentially.
Owner:FUJIFILM CORP

Nutritional compositions comprising phospholipids exhibiting phase separation under gastric conditions, methods of making and uses thereof

The present invention relates to the field of nutritional compositions, methods of providing nutritional compositions and uses thereof. More particularly, the present invention relates to a ready-to-eat powdered infant formula or ready-to-eat powdered growth formula exhibiting desirable gastric digestion characteristics. There is provided a nutritional composition comprising casein, whey protein comprising alpha-lactalbumin (aLac) and beta-lactoglobulin (bLac), and protein-coated fat droplets wherein the composition has a protein content of from 5% to 20% (w / w) based on total solids; the bLac content is at least 3% (w / w) based on the total protein level, and the aLac + bLac content is at least 25% (w / w) based on the total protein level; the fat content is in the range of 10% to 50% (w / w) based on total solids; the fat droplets are coated with an average protein load of 2 to 10 mg / m2, and wherein the weight ratio of casein: (aLacc + bLac) on the fat droplets is at least 4 times the weight ratio of casein: (aLacc + bLac) in the total composition; the level of sphingomyelin per 100 g of the composition is between 70 mg and 200 mg; the level of phospholipids per 100 g of the composition is between 280 mg and 950 mg.
Owner:FRIESLANDCAMPINA NEDERLAND BV

Exosome-like nano-vesicle for gene delivery and preparation method of exosome-like nano-vesicle

The invention relates to an exosome-like nano-vesicle for gene delivery and a preparation method thereof, the exosome-like nano-vesicle comprises a lipid phase and an inner water phase entrapped in the lipid phase, the lipid phase is prepared from cholesterol, phosphatidyl ethanolamine, phosphatidylserine, phosphatidylcholine and sphingomyelin; the inner water phase comprises nucleic acid drugs. The raw material components of the lipid phase are set, the use of cationic lipid and ionizable lipid is avoided, so that the anionic lipid vesicles simulating exosome lipid components can be prepared, the lipid phase entraps the internal water phase containing nucleic acid drugs, and the lipid vesicles have the characteristics of good stability, low toxicity and high transfection efficiency; the exosome has the advantages of limited immunogenicity, high delivery efficiency and enhancement of stability in the in-vivo circulation process of the natural exosome, the preparation process and the final quality are controllable, and commercialized production and clinical transformation are easier to realize.
Owner:XUZHOU YUANYAO PHARM TECH RES INST CO LTD

Application and products of metabolic markers in the preparation of products for monitoring PB neurotoxicity

Disclosed are the use of a metabolic marker in the preparation of a product for monitoring PB neurotoxicity and a product thereof, which can be used for the early diagnosis of PB neurotoxicity with high sensitivity, rapidity, convenience, and accurate and reliable results. The metabolic markers include LysoPE 20:4 / 0:0, creatine, SM d18:1 / 24:0, SM d18:0 / 24:1, LysoPC 18:0, palmitoyl sphingomyelin, phosphocholine, PC 14:0 / 22:1, creatinine, PC 18:3 / 16:0, SM d18:1 / 16:0, sphingosine, choline, LysoPC 18:1, L-carnitine, palmitic acid, PC 18:0 / 20:4, 3-hydroxy-2-octylglutaric acid, L-acetylcarnitine, LysoPC 20:4, LysoPC 16:0, and PC 20:1 / 14:1.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL

Lipid nutritional compositions, products comprising same and uses thereof

The invention relates to a lipid nutritional composition, a product comprising the same and application of the lipid nutritional composition in preparation of a product for promoting structural development of neural stem cells. The lipid nutritional composition comprises: docosahexaenoic acid and / or a metabolic precursor thereof; arachidonic acid and / or a metabolic precursor thereof; and a population of phospholipids consisting of phosphatidylcholine (PC) and / or a metabolic precursor thereof, phosphatidylserine (PS) and / or a metabolic precursor thereof, phosphatidylethanolamine (PE) and / or a metabolic precursor thereof, phosphatidylinositol (PI) and / or a metabolic precursor thereof, and sphingomyelin (SM) and / or a metabolic precursor thereof; wherein the ratio of the molar equivalents of arachidonic acid to the molar equivalents of docosahexaenoic acid, ARA / DHA, is 1-2: 1; and the ratio of the total molar equivalents of the phospholipid population to the molar equivalents of docosahexaenoic acid, PHL / DHA, is 1-8: 1.
Owner:HEILONGJIANG FEIHE DAIRY CO LTD

Nutritional composition comprising milk and egg phospholipids

The present invention provides a nutritional composition especially well suited as an infant nutritional composition, but also as a nutritional support product for pregnant women and as senior nutritional supplement, where phosphatidylcholine and sphingomyelin, and thus choline, also are highly relevant. The present invention provides a nutritional composition which contains choline of high bio-availability.
Owner:AAK AB(PUBL)

Methods and system for use in neonatal diagnostics

The present invention concerns methods and tools for analysing biomarkers useful for diagnosing an individual, in particular a newborn, with a respiratory disease, especially a newborn suffering from respiratory distress syndrome (RDS). The method and tools of the invention can in one embodiment be used for very rapidly detecting the ratio between lecithin and sphingomyelin in very small body fluid samples, e.g. gastric aspirate of a newborn. The invention is thus useful for obtaining a rapid treatment of RDS by administration of surfactant.
Owner:SIME DIAGNOSTICS

Lipid rich in sphingomyelin, preparation method and phospholipid ingredient for infant formula milk powder

The invention provides lipid rich in sphingomyelin, a preparation method and a phospholipid ingredient for infant formula milk powder, and relates to the technical field of dairy product processing.The lipid rich in sphingomyelin and the preparation method thereof have the advantages that primary separation is carried out by the aid of supercritical carbon dioxide extraction technologies, secondary extraction is carried out by the aid of follow-up ethyl alcohol serving as entrainer, non-polar lipid can be effectively removed, and the lipid rich in sphingomyelin can be obtained; and phospholipids with high polarity, especially sphingomyelin, are retained. The ethanol concentration is controlled to be 20% (v / v), so that the solubility and the selective extraction efficiency of lipid rich in sphingomyelin are improved, and a higher sphingomyelin enrichment degree is realized in a final product. Meanwhile, ethanol extraction can be directly combined with a freezing crystallization method, other organic solvents are not introduced into the method, the method is green and safe, complex equipment support is not needed, the technological process is short, operation is easy and convenient, cost is low, and the method is suitable for rapid preparation.
Owner:INNER MONGOLIA DAIRY TECH RES INST CO LTD +2

Liposomal composition for use in a method of treating Parkinson's disease

A method of treating Parkinson's disease in a subject in need thereof. The method comprises administering a liposomal composition, comprising sphingomyelin in a lipid bilayer and a therapeutically effective amount of GM1, to the subject.
Owner:INNOMEDICA HLDG AG